BenevolentAI: against COVID-19 Company
Entity: BenevolentAI
Category: AI for Drug Discovery
Description: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
1. Project: COGENT (COvid-19 Genomic Evaluation of Novel Therapies).
Research Group: With the Cardiovascular Epidemiology Unit at Cambridge.
Summary: The COGENT (COvid-19 Genomic Evaluation of Novel Therapies) portfolio of studies is an international collaboration of investigators lead by the Centre for Naturally Randomized Trials at Cambridge that aims to conduct an integrated suite of studies that a) nests a series of naturally randomized genetic experiments within an ensemble of artificial intelligence algorithms to identify each person’s unique genomic vulnerability to developing severe symptoms if infected with SARS-CoV-2; b) discover what causes some people to be more vulnerable to developing severe symptoms when they become infected with SARS-C0V-2; c) identify targets for therapies that can decrease the risk of developing severe symptoms if infected with SARS-CoV-2; d) conduct a portfolio of pragmatic naturally randomized trials to identify therapies that can potentially most effectively prevent the development of severe symptoms of SARS-C0V-2 infection; and e) use this information to rapidly design and conduct a series of adaptive pragmatic clinical trials to evaluate the clinical safety and efficacy of the identified novel therapies to prevent progression to severe complications among persons infected with SARS-CoV-2.
Collaborators:
BenevolentAI
University of Cambridge
Cambridge Centre for Naturally Randomized Trials
Cambridge Centre for AI in Medicine
TIMI Study Group Harvard Medical School
Imperial College London Clinical Trial Unit
Monash Heart
Oxford Clinical Trial Service Unit (Oxford CTSU)
University of Milan Department of Pharmacological and Biomolecular Sciences
University of Bristol
23and Me
2. Project: AI to treat Coronavirus.
Summary: Benevolent AI have been using their artificial intelligence to identify and analyse the possibilities of already approved drugs being effective in treating coronavirus. They have so far identified Baricitinib as the most promising lead, which is approved for treating rheumatoid arthritis.
“Life sciences and technology companies have a duty to mobilise resources for the public good in this global health emergency that has already claimed so many lives. That’s why we turned our AI drug discovery and development platform toward understanding the body’s response to coronavirus and exploring existing medicines with the potential to address the life threatening complications of the disease. We’re pleased that the Eli Lilly drug we identified as a potential treatment for its anti-viral and anti-inflammatory properties has already been moved forward to clinical testing in America and we look forward to the results”, Baroness Joanna Shields, CEO, BenevolentAI.
Category: AI for Drug Discovery
Description: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
1. Project: COGENT (COvid-19 Genomic Evaluation of Novel Therapies).
Research Group: With the Cardiovascular Epidemiology Unit at Cambridge.
Summary: The COGENT (COvid-19 Genomic Evaluation of Novel Therapies) portfolio of studies is an international collaboration of investigators lead by the Centre for Naturally Randomized Trials at Cambridge that aims to conduct an integrated suite of studies that a) nests a series of naturally randomized genetic experiments within an ensemble of artificial intelligence algorithms to identify each person’s unique genomic vulnerability to developing severe symptoms if infected with SARS-CoV-2; b) discover what causes some people to be more vulnerable to developing severe symptoms when they become infected with SARS-C0V-2; c) identify targets for therapies that can decrease the risk of developing severe symptoms if infected with SARS-CoV-2; d) conduct a portfolio of pragmatic naturally randomized trials to identify therapies that can potentially most effectively prevent the development of severe symptoms of SARS-C0V-2 infection; and e) use this information to rapidly design and conduct a series of adaptive pragmatic clinical trials to evaluate the clinical safety and efficacy of the identified novel therapies to prevent progression to severe complications among persons infected with SARS-CoV-2.
Collaborators:
BenevolentAI
University of Cambridge
Cambridge Centre for Naturally Randomized Trials
Cambridge Centre for AI in Medicine
TIMI Study Group Harvard Medical School
Imperial College London Clinical Trial Unit
Monash Heart
Oxford Clinical Trial Service Unit (Oxford CTSU)
University of Milan Department of Pharmacological and Biomolecular Sciences
University of Bristol
23and Me
2. Project: AI to treat Coronavirus.
Summary: Benevolent AI have been using their artificial intelligence to identify and analyse the possibilities of already approved drugs being effective in treating coronavirus. They have so far identified Baricitinib as the most promising lead, which is approved for treating rheumatoid arthritis.
“Life sciences and technology companies have a duty to mobilise resources for the public good in this global health emergency that has already claimed so many lives. That’s why we turned our AI drug discovery and development platform toward understanding the body’s response to coronavirus and exploring existing medicines with the potential to address the life threatening complications of the disease. We’re pleased that the Eli Lilly drug we identified as a potential treatment for its anti-viral and anti-inflammatory properties has already been moved forward to clinical testing in America and we look forward to the results”, Baroness Joanna Shields, CEO, BenevolentAI.
Connections
Connections from
Technology:
AI for Drug Discovery
Headquarters:
United Kingdom
Founded Date:
1905
Employees Number:
51-100
Funding Status:
N/A
Register and Claim Ownership